However, Pfizer supposedly contacted RAP of a T/O bid and signed the NDA in December so well before the COVID-19 recruitment for the studies completed. Pfizer has a digital medicine department so they are interested in breaking into this sector and ResAppDx is a clear advantage to their competitors in this space since respiratory disease is the most common disease and consultation.
- Forums
- ASX - By Stock
- RAP
- RAP media thread.
RAP media thread., page-3121
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 276 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)